Lucid closes Nasdaq initial public offering

By LabPulse.com staff writers

October 20, 2021 -- The cancer prevention medical diagnostics firm Lucid Diagnostics, a subsidiary of PAVmed, has closed its initial public offering (IPO).

It closed 5 million shares of common stock at a price to the public of $14 per share for total gross proceeds of $70 million before deducting underwriting discounts and commissions and estimated offering expenses.

Additionally, Lucid has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the IPO price minus underwriting discounts and commissions.

Lucid Diagnostics files for IPO on Nasdaq exchange
Lucid Diagnostics has filed for an initial public offering (IPO), and the company's shares will be traded on the Nasdaq stock exchange under the symbol...
Lucid launches EsoGuard pilot test at centers in Ariz.
Lucid Diagnostics has launched three test centers in Phoenix, where patients are undergoing esophageal precancer testing in a pilot test of the company's...

Copyright © 2021 LabPulse.com

Last Updated ls 10/20/2021 4:36:10 PM